Emsam Antidepressant Patch Approved; April Launch Anticipated
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol/Somerset’s product avoids MAOI-class dietary restrictions at the lowest dose.
You may also be interested in...
Abilify Discmelt Launching At 19% Premium To Regular Tablets
Bristol/Otsuka’s aripiprazole is the third antipsychotic to offer a quick-dissolving version.
Abilify Discmelt Launching At 19% Premium To Regular Tablets
Bristol/Otsuka’s aripiprazole is the third antipsychotic to offer a quick-dissolving version.
Selegiline Approved For Parkinson’s In Orally Disintegrating Tablet Form
Valeant’s Zelapar clears FDA after two “approvable” letters.